Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines
Overall the evidence base for the efficacy and effectiveness of newer and enhanced influenza vaccines appears limited at present, with a number of potentially relevant studies identified as ongoing.
Review of the scientific literature on drivers and barriers of seasonal influenza vaccination coverage in the EU/EEA
The report aims to provide a critical review of evidence on the barriers and drivers of seasonal influenza vaccination coverage in the EU/EEA. The report focuses on high-risk groups where high coverage of seasonal flu vaccination is most important. The 2009 Council of the European Union Recommendation on seasonal influenza vaccination encourages countries to implement measures that would increase seasonal influenza vaccination uptake to at least 75% for defined older age groups, and, if possible, for other risk groups. In support of this, the ECDC report summarises the evidence on what are the barriers and what are the drivers for seasonal influenza vaccination by each risk group
Table of contributions for the expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza
The 'Table of contributions' contains all comments received through a public consultation on this topic and lists ECDC’s responses to those comments.
The 2009 A(H1N1) pandemic in Europe, a review of the experience
This extended report aims to provide a broad overview of the epidemiology and virology of the 2009 pandemic in the European Union and European Economic Area countries. The main trends and information are derived from the analysis and interpretation of the epidemiological and virological data and other analyses provided to the European Centre for Disease Prevention and Control’s European Surveillance system through the European Influenza Surveillance Network.
Interim technical guidance on public health use of influenza antivirals during influenza pandemics
Antiviral drugs are an important addition to the public health arsenal against influenza. This interim guidance discusses the options for their effective use, especially during a pandemic.
Interim technical guidance on use of specific pandemic influenza vaccines during the H1N1 2009 pandemic
This interim guidance outlines the possible strategies that countries may wish to adopt in the deployment of a pandemic-specific vaccine, considering the two objectives of vaccination: protecting those at greatest risk of severe disease and maintaining essential services.
Interim ECDC public health guidance on case and contact management for the new influenza A(H1N1) virus infection
ECDC intends to produce a series of interim guidance documents on suggested procedures to be put in place in order to reduce the risk of transmission of the new influenza A(H1N1) virus. This guidance only applies to a situation when there are relatively few persons under investigation, and will be revised if there seems to be a wider spread.
Technical guidance on mitigation and delaying (or ‘containment’)strategies as the new influenza A(H1N1) virus comes into Europe
As epidemics of the new influenza A(H1N1) virus are extending globally, some European countries are considering how robustly to undertake case-finding among the first cases and whether to pursue and treat contacts.
Systematic review on the incubation and infectiousness/shedding period of communicable diseases in children
Illnesses caused by infectious diseases are common in children in schools or other childcare settings. Currently there is no common EU approach to the control of communicable diseases in schools or other childcare settings, and existing information is uncertain.